| abstract |
The deuterated compound represented by the formula (I) or an optical isomer thereof, a metavariant, a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvent product, wherein the deuterated compound is heavy. It shows better pharmacokinetics, higher maximum blood concentration, higher exposure and longer half-life compared to pre-hydrogenated compounds and has better metabolic performance. In addition, deuterated compounds can effectively inhibit the activity of FAK and have great potential for application in the preparation of FAK inhibitors and / or drugs for treating cancer. At the same time, the deuterated compound can exert a synergistic effect when used in combination with an anticancer drug (for example, PD-1 inhibitor), significantly improves the tumor suppressing effect, and is superior in clinical cancer treatment. Provide choices. |